AI Insight
A randomized controlled trial published in The Lancet Healthy Longevity found that adults aged 75 and older with no history of heart disease or stroke who discontinued statin medication had similar three-year survival rates compared to those who continued taking statins. However, participants who stopped statins experienced approximately 50% increases in LDL cholesterol levels. The study focused on primary prevention in elderly populations without existing cardiovascular disease.
Why it matters
This research challenges the routine continuation of statins for primary prevention in older adults, suggesting that deprescribing may be safe in select elderly populations without cardiovascular disease history. The findings could inform clinical decisions about medication management in aging patients, potentially reducing polypharmacy and associated side effects while maintaining survival outcomes.
Understand the Science
Stopping statins in adults 75 and older with no history of heart disease or stroke does not increase the risk of death over three years compared with continuing statins, although “bad” cholesterol rose around 50% in those who stopped, according to a randomized controlled trial published in The Lancet Healthy Longevity. Statins are a key medication for the prevention of atherosclerotic cardiovascular disease, a specific type of cardiovascular disease caused by the buildup of fatty plaque (atherosclerosis) inside the arteries.
Source: Adults 75 and older who stopped statins had similar three-year survival, trial finds